First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resisted prior checkpoint therapy and who had poor-risk disease features In the overall BOT+BAL treated ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. First presentation of BOT+BAL melanoma data in ...
AgenusInc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus’ multifunctional ...
The BOT+BAL combination arm included 36 heavily pretreated patients with advanced cutaneous melanoma. Most had disease that had resisted prior checkpoint therapy, and many had poor-risk features, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results